Open AccessCost-minimisation analysis of rectal cancer neoadjuvant chemoradiotherapy based on fluoropyrimidines (capecitabine versus 5-fluorouracil)
Author(s) -
Sergio Marín,
Laia Pérez-Cordón,
Francesc Salvà,
M. Valero Camps,
Lluís Campins,
P. Lianes
Publication year - 2020
Publication title -
european journal of hospital pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.313
H-Index - 14
eISSN - 2047-9964
pISSN - 2047-9956
DOI - 10.1136/ejhpharm-2019-002156
Subject(s) - capecitabine , medicine , fluorouracil , colorectal cancer , cost minimization analysis , chemoradiotherapy , minimisation (clinical trials) , surgery , tegafur , neoadjuvant therapy , chemotherapy , cancer , breast cancer , pathology
The current standard treatment for patients with rectal cancer stage II-III is neoadjuvant chemoradiotherapy followed by surgery. Neoadjuvant chemoradiotherapy can be performed with 5-fluorouracil (5-FU) or capecitabine (CPC) considered to be equivalent therapies. Medication cost is higher for CPC than for 5-FU, however, the administration of continuous 5-FU intravenous infusion is related to other costs such as those associated with outpatient facilities or central venous catheter insertion.